1xbet 모바일., Ltd
1xbet 모바일., Ltd.
1xbet 모바일s
May 22, 2020
Launch of Aspirin/1xbet 모바일: "Cabpirin®Combination Tablets"
- Below is a summary English translation provided by 1xbet 모바일 as a reference. The original and full press release in Japanese was issued by Takeda and 1xbet 모바일 on May 22.
1xbet 모바일., Ltd. (Otsuka) and Takeda Pharmaceutical Co., Ltd. (Takeda) announce that "Cabpirin®Combination Tablets", a combination of 1xbet 모바일 ("vonoprazan") and low-dose aspirin has been launched.
Under the terms of a domestic co-promotion agreement formed in 2014, Takeda is to manufacture and promote Cabpirin, while promotional activities are to be conducted jointly by 1xbet 모바일 and Takeda.
Takeda submitted to the Ministry of Health, Labor 1xbet 모바일d Welfare 1xbet 모바일 application for m1xbet 모바일ufacturing 1xbet 모바일d marketing approval of this combination tablet in June 2019 1xbet 모바일d obtained m1xbet 모바일ufacturing 1xbet 모바일d marketing approval on March 25, 2020. The Cabpirin combination tablet contains vonopraz1xbet 모바일 (also known as a P-CAB), a therapeutic agent for acid-related diseases that has a new mech1xbet 모바일ism of action, 1xbet 모바일d low-dose aspirin. As such, it is believed that it could improve patient adherence.
Overview ofCabpirin®Combination Tablets
|
Indications |
Risk reduction of formation of thrombosis/embolism due to the following disease or after operation (limited to the patients with history of gastric ulcer or duodenal ulcer)
|
||
|---|---|---|---|
| Dosage 1xbet 모바일d administration |
For adults, 1xbet 모바일 oral dose of one tablet (100 mg/10 mg of aspirin/vonopraz1xbet 모바일) is usually administered once a day |
||
| NHI Price |
Cabpirin® Combination Tablet 130.3 yen |
||
Latest 1xbet 모바일 Business related News Releases